Rare variant associations with plasma protein levels in the UK Biobank
Ryan S. Dhindsa (),
Oliver S. Burren,
Benjamin B. Sun,
Bram P. Prins,
Dorota Matelska,
Eleanor Wheeler,
Jonathan Mitchell,
Erin Oerton,
Ventzislava A. Hristova,
Katherine R. Smith,
Keren Carss,
Sebastian Wasilewski,
Andrew R. Harper,
Dirk S. Paul,
Margarete A. Fabre,
Heiko Runz,
Coralie Viollet,
Benjamin Challis,
Adam Platt,
Dimitrios Vitsios,
Euan A. Ashley,
Christopher D. Whelan,
Menelas N. Pangalos,
Quanli Wang and
Slavé Petrovski ()
Additional contact information
Ryan S. Dhindsa: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Oliver S. Burren: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Benjamin B. Sun: Translational Sciences, Research & Development, Biogen Inc.
Bram P. Prins: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Dorota Matelska: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Eleanor Wheeler: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Jonathan Mitchell: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Erin Oerton: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Ventzislava A. Hristova: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Katherine R. Smith: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Keren Carss: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Sebastian Wasilewski: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Andrew R. Harper: Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca
Dirk S. Paul: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Margarete A. Fabre: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Heiko Runz: Translational Sciences, Research & Development, Biogen Inc.
Coralie Viollet: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Benjamin Challis: Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca
Adam Platt: Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca
Dimitrios Vitsios: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Euan A. Ashley: Stanford University
Christopher D. Whelan: Translational Sciences, Research & Development, Biogen Inc.
Menelas N. Pangalos: BioPharmaceuticals R&D, AstraZeneca
Quanli Wang: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Slavé Petrovski: Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
Nature, 2023, vol. 622, issue 7982, 339-347
Abstract:
Abstract Integrating human genomics and proteomics can help elucidate disease mechanisms, identify clinical biomarkers and discover drug targets1–4. Because previous proteogenomic studies have focused on common variation via genome-wide association studies, the contribution of rare variants to the plasma proteome remains largely unknown. Here we identify associations between rare protein-coding variants and 2,923 plasma protein abundances measured in 49,736 UK Biobank individuals. Our variant-level exome-wide association study identified 5,433 rare genotype–protein associations, of which 81% were undetected in a previous genome-wide association study of the same cohort5. We then looked at aggregate signals using gene-level collapsing analysis, which revealed 1,962 gene–protein associations. Of the 691 gene-level signals from protein-truncating variants, 99.4% were associated with decreased protein levels. STAB1 and STAB2, encoding scavenger receptors involved in plasma protein clearance, emerged as pleiotropic loci, with 77 and 41 protein associations, respectively. We demonstrate the utility of our publicly accessible resource through several applications. These include detailing an allelic series in NLRC4, identifying potential biomarkers for a fatty liver disease-associated variant in HSD17B13 and bolstering phenome-wide association studies by integrating protein quantitative trait loci with protein-truncating variants in collapsing analyses. Finally, we uncover distinct proteomic consequences of clonal haematopoiesis (CH), including an association between TET2-CH and increased FLT3 levels. Our results highlight a considerable role for rare variation in plasma protein abundance and the value of proteogenomics in therapeutic discovery.
Date: 2023
References: Add references at CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
https://www.nature.com/articles/s41586-023-06547-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:622:y:2023:i:7982:d:10.1038_s41586-023-06547-x
Ordering information: This journal article can be ordered from
https://www.nature.com/
DOI: 10.1038/s41586-023-06547-x
Access Statistics for this article
Nature is currently edited by Magdalena Skipper
More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().